

Heart Valve disease (hVd) e ects around 1 in 2 of people over 65 to some extent.

Those with severe HVD have a five-year survival rate of only 3% without treatment which is worse than many common cancers. With the number of people in the UK with moderate to severe HVD set to grow from the current 1.5 million to 3.3 million by 2056, Edwards Lifesciences wanted to better understand the needs of this large patient group.

Edwards Lifesciences selected Quantis to deliver real insight into the existing HVD situation. Using hospital